{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:15:54Z","timestamp":1791234954245,"version":"4.1.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,9,29]],"date-time":"2012-09-29T00:00:00Z","timestamp":1348876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s10620-012-2405-z","type":"journal-article","created":{"date-parts":[[2012,9,30]],"date-time":"2012-09-30T13:23:02Z","timestamp":1349011382000},"page":"797-806","source":"Crossref","is-referenced-by-count":32,"title":["Infliximab for Crohn\u2019s Disease: The First 500 Patients Followed Up Through 2009"],"prefix":"10.1007","volume":"58","author":[{"given":"Jennifer L.","family":"Seminerio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabin","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Sandborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,29]]},"reference":[{"key":"2405_CR1","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/S0140-6736(07)60751-X","volume":"369","author":"DC Baumgart","year":"2007","unstructured":"Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641\u20131657.","journal-title":"Lancet"},{"key":"2405_CR2","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1056\/NEJM199710093371502","volume":"337","author":"SR Targan","year":"1997","unstructured":"Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s disease cA2 study group. N Engl J Med. 1997;337:1029\u20131035.","journal-title":"N Engl J Med"},{"key":"2405_CR3","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","volume":"340","author":"DH Present","year":"1999","unstructured":"Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn\u2019s disease. N Engl J Med. 1999;340:1398\u20131405.","journal-title":"N Engl J Med"},{"key":"2405_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541\u20131549.","journal-title":"Lancet"},{"key":"2405_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1056\/NEJMoa030815","volume":"350","author":"BE Sands","year":"2004","unstructured":"Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn\u2019s disease. N Engl J Med. 2004;350:876\u2013885.","journal-title":"N Engl J Med"},{"key":"2405_CR6","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha- neutralizing agent. N Engl J Med. 2001;345:1098\u20131104.","journal-title":"N Engl J Med"},{"key":"2405_CR7","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1002\/art.10583","volume":"46","author":"JH Lee","year":"2002","unstructured":"Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum. 2002;46:2565\u20132570.","journal-title":"Arthritis Rheum"},{"key":"2405_CR8","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1002\/art.10679","volume":"46","author":"SL Brown","year":"2002","unstructured":"Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the food and drug administration. Arthritis Rheum. 2002;46:3151\u20133158.","journal-title":"Arthritis Rheum"},{"key":"2405_CR9","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/j.cgh.2009.01.004","volume":"7","author":"CA Siegel","year":"2009","unstructured":"Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn\u2019s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874\u2013881.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2405_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/MPG.0b013e31802f6424","volume":"44","author":"AC Mackey","year":"2007","unstructured":"Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265\u2013267.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"2405_CR11","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1111\/j.1572-0241.2000.03366.x","volume":"95","author":"RJ Farrell","year":"2000","unstructured":"Farrell RJ, Shah SA, Lodhavia PJ, et al. Clinical experience with infliximab therapy in 100 patients with Crohn\u2019s disease. Am J Gastroenterol. 2000;95:3490\u20133497.","journal-title":"Am J Gastroenterol"},{"key":"2405_CR12","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1111\/j.1572-0241.2000.03363.x","volume":"95","author":"RD Cohen","year":"2000","unstructured":"Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn\u2019s disease: first anniversary clinical experience. Am J Gastroenterol. 2000;95:3469\u20133477.","journal-title":"Am J Gastroenterol"},{"key":"2405_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/j.1572-0241.2001.03612.x","volume":"96","author":"E Ricart","year":"2001","unstructured":"Ricart E, Panaccione R, Loftus EV, et al. Infliximab for Crohn\u2019s disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol. 2001;96:722\u2013729.","journal-title":"Am J Gastroenterol"},{"key":"2405_CR14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1046\/j.1365-2036.2001.01092.x","volume":"15","author":"ID Arnott","year":"2001","unstructured":"Arnott ID, McDonald D, Williams A, et al. Clinical use of infliximab in Crohn\u2019s disease: the Edinburgh experience. Aliment Pharmacol Ther. 2001;15:1639\u20131646.","journal-title":"Aliment Pharmacol Ther"},{"key":"2405_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/00054725-200203000-00002","volume":"8","author":"DW Hommes","year":"2002","unstructured":"Hommes DW, van de Heisteeg BH, van der Spek M, et al. Infliximab treatment for Crohn\u2019s disease: one-year experience in a Dutch academic hospital. Inflamm Bowel Dis. 2002;8:81\u201386.","journal-title":"Inflamm Bowel Dis"},{"key":"2405_CR16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1155\/2002\/379307","volume":"16","author":"C Sample","year":"2002","unstructured":"Sample C, Bailey RJ, Todoruk D, et al. Clinical experience with infliximab for Crohn\u2019s disease: the first 100 patients in Edmonton, Alberta. Can J Gastroenterol. 2002;16:165\u2013170.","journal-title":"Can J Gastroenterol"},{"key":"2405_CR17","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","volume":"126","author":"JF Colombel","year":"2004","unstructured":"Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn\u2019s disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19\u201331.","journal-title":"Gastroenterology"},{"key":"2405_CR18","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1136\/gut.2008.155812","volume":"58","author":"F Schnitzler","year":"2009","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn\u2019s disease: results from a single-centre cohort. Gut. 2009;58:492\u2013500.","journal-title":"Gut"},{"key":"2405_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/gut.2008.163642","volume":"58","author":"H Fidder","year":"2009","unstructured":"Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501\u2013508.","journal-title":"Gut"},{"key":"2405_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cgh.2010.09.026","volume":"9","author":"M Cottone","year":"2011","unstructured":"Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30\u201335.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2405_CR21","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ibd.21416","volume":"17","author":"L Biancone","year":"2011","unstructured":"Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn\u2019s disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758\u2013766.","journal-title":"Inflamm Bowel Dis"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2405-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10620-012-2405-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2405-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-012-2405-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T04:09:55Z","timestamp":1581998995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10620-012-2405-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,29]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2405"],"URL":"https:\/\/doi.org\/10.1007\/s10620-012-2405-z","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,29]]}}}